Clinical Trials Logo

Clinical Trial Summary

Type 2 Diabetes (T2D) in obese youth is often preceded by a prediabetic state called: Impaired Glucose Tolerance (IGT), which is associated with a pre-existing defect in insulin secretion. This study intends to determine if genetic factors are associated with defects in insulin secretion, the incretin system and hepatic insulin resistance in obese adolescents. The long-term goal of this study is to generate information on both the genetics as well as the pathophysiology of Type 2 Diabetes in Youth, which ultimately might guide the investigators towards better preventive and treatment avenues.


Clinical Trial Description

The Specific Aims of this study are: Aim 1a. To delineate the effects of TCF7L2 rs7903146 on functional Beta-Cell Capacity in obese adolescents with Impaired Glucose Tolerance (IGT) and pre-IGT. Aim 1b. To determine if the risk genotype in TCF7L2 is associated with worsening in beta cell function longitudinally, thereby affecting changes in glucose tolerance. Aim 2. To examine the functional effect of the rs7903146 variant in the TCF7L2 gene on a) incretin effect in obese adolescents with IGT and pre-IGT. Aim 3. To determine the functional effects of TCF7L2 rs7903146 SNP on hepatic glucose fluxes in obese adolescents with IGT and pre-IGT. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03195400
Study type Observational
Source Yale University
Contact
Status Completed
Phase
Start date March 1, 2017
Completion date August 12, 2022

See also
  Status Clinical Trial Phase
Completed NCT03194152 - Peanut Consumption and Cardiovascular Disease Risk in a Chinese Population N/A
Enrolling by invitation NCT05760677 - Study on the Efficacy and Safety of Chiglitazar Sodium in PCOS With T2DM Phase 1
Not yet recruiting NCT05980754 - Clinical Study on Exploring High Risk Factors Inducing the Progress of Diabetes
Recruiting NCT04501341 - BM-MNC and UCMSC for Type 2 Diabetes Mellitus Patients Phase 1/Phase 2
Active, not recruiting NCT05662332 - A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1) Phase 3
Recruiting NCT05536804 - A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes Phase 2
Completed NCT04011904 - The Role of Traditional or Western Diet in the TBC1D4 Gene on Glucose Homeostasis in Greenland Inuits N/A
Active, not recruiting NCT05260021 - A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both Phase 3